Aviceda Therapeutics is a private clinical-stage biotech company focused on the next generation of glyco-immune therapeutics that leverage the Glyco-Code® technology platform to address inflammatory diseases of the innate immune system including geographic atrophy (GA) from age-related macular degeneration (AMD), cancer, fibrosis, neurologic diseases, and others.
At Aviceda, we exploit a unique family of receptors expressed on all innate immune cells, and their associated glycobiological interactions, to develop transformative medicines for a variety of pathologies with current unmet needs. We combine the power of our biology with our innovative cell-based high-throughput screening platform and proprietary nanoparticle technology to modulate the immune response specifically and profoundly.
Aviceda has assembled a world-class, cross-disciplinary team of recognized scientists, clinicians, and drug developers to tackle devastating ocular and systemic degenerative, fibrotic, and immuno-inflammatory diseases.
Our primary offices and lab are based in Cambridge, Massachusetts, though we have subsidiary offices and labs in Belfast, Northern Ireland, and lab association agreements at the University of Georgia and in Utrecht, Netherlands.